Skip to main content
SpringerLink
Log in

Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the GH-releasing activity of a synthetic hexapeptide, GHRP-6, in the Prader-Willi syndrome (PWS). Sixteen PWS patients (7 males and 9 females, aged 12.7–38.3 yr), 15 with essential obesity (OB) (7 males and 8 females, aged 12.9–42.9 yr), and 8 short normal children (SN; 3 males and 5 females, aged 10.2–14.3 yr) underwent 2 tests on separate occasions, being challenged with GHRP-6 (1 μg/kg, iv) or GHRH (1 μg/kg, iv)+PD (60 or 120 mg for children or adults, po). Moreover, in 11 patients with PWS and in the group of SN, the GH response to at least 2 stimulation tests had been previously determined. GH was analyzed either as mean peak values (GHp, mcg/l), or as the area under the curve (AUC, mcg/l/h) and the net incremental area under the curve (nAUC, mcg/l/h). In the group of PWS subjects, GH responses to both GHRP-6 (GHp: 11.4±2.0; AUC: 588±113; nAUC: 483±108) and GHRH+PD (GHp: 7.3±1.8; AUC: 486±122; nAUC: 371±250) were significantly lower than those observed either in OB (GHRP-6: GHp: 25.7±3.2, p<0.003; AUC: 1833±305, p<0.005; nAUC: 1640±263, p<0.0001. GHRH+PD: GHp: 15.1±2.4, p<0.009; AUC: 1249±248, p<0.003; nAUC: 918±230, p<0.006) or in SN patients (GHRP-6: GHp: 39.1±3.1, p<0.0001; AUC: 2792±158, p<0.0001; nAUC: 2705±165, p<0.00005. GHRH+PD: GHp: 27.5±3.7, p<0.0001; AUC: 1873±251, p<0.0001; nAUC: 1692±219, p<0.0005). Unlike control groups, in PWS patients GH levels after GHRP-6 did not differ from those obtained after GHRH+PD. Interestingly, low IGF-I values were present in all PWS subjects. Furthermore, no patient with PWS showed normal GH response to the previously performed GH stimulation tests. As already reported, GH release after GHRP-6 or GHRH+PD was significantly lower in OB than in SN subjects. In conclusion, our data indicate that: 1) GH response to GHRP-6 is clearly impaired in PWS; 2) the blunted GH responses to the provocative stimuli in PWS are not an artifact of obesity; 3) short stature in PWS is caused by a complex dysfunction of the hypothalamo-pituitary structures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bowers C.Y., Sartor A.O., Reynolds G.A., Badger T.M. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991, 128: 2027–2035.

    Article  CAS  PubMed  Google Scholar 

  2. Howard A., Feighner S., Cully D., Arena J.P., Liberator P.A., Rosenblum C.I., Hamelin M., Hreniuk D.L., Palyha O.C., Anderson J., Paress P.S., Diaz C., Chou M., Liu K.K., McKee K.K., Pong S.S., Chaung L.Y.P., Elbrecht A., Dashkevicz M., Heavens R., Rigby M., Sirinathsinghji D.J.S., Dean D.C., Melillo D.G., Patchett A.A., Nargund R.P., Griffin P.R., DeMartino J.A., Gupta S.K., Schaeffer J.M., Smith R.G., Van der Ploeg L.H.T. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996, 273: 974–977.

    Article  CAS  PubMed  Google Scholar 

  3. Guillaume V., Magnan E., Cataldi M., Dutour A., Sauze N., Renard M., Razafindraibe H., Conte-Devolx B., Deghenghi R., Lenaerts V., Oliver C. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology 1994, 135: 1073–1076.

    CAS  PubMed  Google Scholar 

  4. Bowers C.Y. Editorial: On a peptidomimetic growth hormone-releasing peptide. J. Clin. Endocrinol. Metab. 1994, 79: 940–942.

    CAS  PubMed  Google Scholar 

  5. Korbonits M., Grossman A.B. Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends Endocrinol. Metab. 1995, 6: 43–49.

    Article  CAS  PubMed  Google Scholar 

  6. Micic D., Popovic V., Kendereski A., Macut D., Casanueva F.F., Dieguez C. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood. Clin. Endocrinol. (Oxf.) 1995, 42: 191–194.

    Article  CAS  Google Scholar 

  7. Penalva A., Carballo A., Pombo M., Casanueva F.F., Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6 induced GH secretion in man. J. Clin. Endocrinol. Metab. 1993, 76: 168–171.

    CAS  PubMed  Google Scholar 

  8. Penalva A., Pombo M., Carballo A., Barreiro J., Casanueva F.F., Dieguez C. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clin. Endocrinol. (Oxf.) 1993, 38: 87–91.

    Article  CAS  Google Scholar 

  9. Popovic V., Damjanovic S., Micic D., Djurovic M., Dieguez C., Casanueva F.F. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J. Clin. Endocrinol. Metab. 1995, 80: 942–947.

    CAS  PubMed  Google Scholar 

  10. Popovic V., Damjanovic S., Micic D., Petakov M., Dieguez C., Casanueva F.F. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone, and GH-releasing peptide-6. J. Clin. Endocrinol. Metab. 1994, 79: 456–460.

    CAS  PubMed  Google Scholar 

  11. Ghigo E., Arvat E., Muccioli G., Camanni F. Growth hormone-releasing peptides. Eur. J. Endocrinol. 1997, 136: 445–460.

    Article  CAS  PubMed  Google Scholar 

  12. Pombo M., Leal Cerro A., Barreiro J., Penalva A., Peino R., Mallo F., Dieguez C., Casanueva F.F. Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. J. Pediatr. Endocrinol. Metab. 1996, 9 (Suppl. 3): 333–338.

    PubMed  Google Scholar 

  13. Scacchi M., Pincelli A.I., Cavagnini F. Growth hormone in obesity. Int. J. Obes. Relat. Metab. Disord. 1999, 23: 260–271.

    Article  CAS  PubMed  Google Scholar 

  14. Argente J., Caballo N., Barrios V., Munoz M.T., Pozo J., Chowen J.A., Hernandez M. Disturbances in the growth hormone-insulin-like growth factor axis in children and adolescents with different eating disorders. Horm. Res. 1997, 48 (Suppl. 4): 16–18.

    Article  CAS  PubMed  Google Scholar 

  15. Cordido F., Penalva A., Peino R., Casanueva F.F., Dieguez C. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6 and pyridostigmine in normal and obese subjects. Metabolism 1995, 44: 745–748.

    Article  CAS  PubMed  Google Scholar 

  16. Burd L., Veselly B., Martsolf J., Kerbeshian J. Prevalence study of Prader-Willi syndrome. Lancet 1985, 2: 828–829.

    Google Scholar 

  17. Donaldson M.D.C., Chu C.E., Cooke A., Wilson A., Greene S.A., Stephenson J.B.P. The Prader-Willi syndrome. Arch. Dis. Child. 1994, 70: 58–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Grugni G., Guzzaloni G., Moro D., Bettio D., De Medici C., Morabito F. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome. Clin. Endocrinol. (Oxf.) 1998, 48: 769–775.

    Article  CAS  Google Scholar 

  19. Cappa M., Grossi A., Borrelli P., Ghigo E., Bellone J., Benedetti S., Carta D., Loche S. Growth Hormone (GH) response to combined pyridostigmine and GH-Releasing Hormone administration in patients with Prader-Labhardt-Willi syndrome. Horm. Res. 1993, 39: 51–55.

    Article  CAS  PubMed  Google Scholar 

  20. Holm V.A., Cassidy S.B., Butler M.G., Hanchett J.M., Greenswag L.R., Whitman B.Y., Greenberg F. Prader-Willi syndrome: Consensus diagnostic criteria. Pediatrics 1993, 91: 398–402.

    CAS  PubMed  Google Scholar 

  21. Rolland-Cachera M.F., Sempè M., Guilloud-Bataille M., Patois E., Pequinot-Gugenbuhl F., Fautrad V. Adiposity indices in children. Am. J. Clin. Nutr. 1982, 36: 178–184.

    CAS  PubMed  Google Scholar 

  22. Joint FAO/WHO/UNU: Expert consultation. Energy and protein requirements. WHO Technical Report Series, no. 724, WHO, Geneva, 1985.

    Google Scholar 

  23. Tanner J.M., Whitehouse R.H., Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. Arch. Dis. Child. 1966, 41: 613–635.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Marshall W.A., Tanner J.M. Variation in the pattern of pubertal changes in girls. Arch. Dis. Child. 1969, 44: 291–303.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Marshall W.A., Tanner J.M. Variation in the pattern of pubertal changes in boys. Arch. Dis. Child. 1970, 45: 13–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Spiliotis B.E., August G.P., Hung W., Mendelson W., Bercu B.B. Growth hormone neurosecretory dysfunction: a treatable cause of short stature. JAMA 1984, 251: 2223–2230.

    Article  CAS  PubMed  Google Scholar 

  27. Dammacco F., Boghen M.F., Camanni F., Cappa M., Ferrari C., Ghigo E., Giordano G., Loche S., Minuto F., Mucci M., Muller E.E., the Italian Collaborative Group of Neuroendocrinology. Somatotropic function in short stature: evaluation by integrated auxological and hormonal indices in 214 children. J. Clin. Endocrinol. Metab. 1993, 77: 68–72.

    CAS  PubMed  Google Scholar 

  28. Loche S., Pintus S., Cella S.G., Boghen M., Vannelli V., Benso L., Muller E.E., Corda R., Pintor C. The effect of galanin on baseline and GHRH-induced growth hormone secretion in obese children. Clin. Endocrinol. (Oxf.) 1990, 33: 187–192.

    Article  CAS  Google Scholar 

  29. Angulo M., Castro-Magana M., Mazur B., Canas J.A., Vitollo P.M., Sarrantonio M. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J. Pediatr. Endocrinol. Metab. 1996, 9: 393–400.

    Article  CAS  PubMed  Google Scholar 

  30. Vanderschueren-Lodeweyckx M. The effect of simple obesity on growth and growth hormone. Horm. Res. 1993, 40: 23–30.

    Article  CAS  PubMed  Google Scholar 

  31. Wollmann H.A., Schultz U., Grauer M.L., Ranke M.B. Reference values for height and weight in Prader-Willi syndrome based on 315 patients. Eur. J. Pediatr. 1998, 157: 634–642.

    Article  CAS  PubMed  Google Scholar 

  32. Thacker M.J., Hainline B., St. Dennis-Feezle L., Johnson N.B., Pescovitz O.H. Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. Horm. Res. 1998, 49: 216–220.

    Article  CAS  PubMed  Google Scholar 

  33. Costeff H., Holm V.A., Ruvalcaba R., Shaver J. Growth hormone secretion in Prader-Willi syndrome. Acta Paediatr. Scand. 1990, 79: 1059–1062.

    Article  CAS  PubMed  Google Scholar 

  34. Arvat E., Camanni F., Ghigo E. Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Acta Paediatr. 1997, 423 (Suppl.): 92–96.

    Article  CAS  Google Scholar 

  35. Loche S., Cambiaso P., Carta D., Setzu S., Imbimbo B.P., Borrelli P., Pintor C., Cappa M. The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. J. Clin. Endocrinol. Metab. 1995, 80: 674–678.

    CAS  PubMed  Google Scholar 

  36. Loche S., Cambiaso P., Merola B., Colao A., Faedda A., Imbimbo B.P., Deghenghi R., Lombardi G., Cappa M. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency. J. Clin. Endocrinol. Metab. 1995, 80: 2692–2696.

    CAS  PubMed  Google Scholar 

  37. Pombo M., Barreiro J., Penalva A., Peino R., Dieguez C., Casanueva F.F. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. J. Clin. Endocrinol. Metab. 1995, 80: 3180–3184.

    PubMed  Google Scholar 

  38. Sieg K.G., Gaffney G.R., Preston D.F., Erikson H.M. SPECT brain imaging of Prader-Willi syndrome using technetium-99m-hexamethylpropyleneamine oxime. Am. J. Med. Genet. 1991, 41: 529.

    Google Scholar 

  39. Butler M.G., Kessler R.M. Positron emission tomography of three adult patients with Prader-Willi syndrome. Dysmorph. Clin. Genet. 1992, 6: 30–31.

    Google Scholar 

  40. Miller L., Angulo M., Price D., Taneja S. MR of the pituitary in patients with Prader-Willi syndrome: size determination and imaging findings. Pediatr. Radiol. 1996, 26: 43–47.

    Article  CAS  PubMed  Google Scholar 

  41. Corrias A., Bellone J., Beccaria L., Bosio L., Trifirò G., Livieri C., Ragusa L., Salvatoni A., Andreo M., Ciampalini P., Tonini G., Crinò A. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of somatotroph responsiveness to various provocative stimuli. J. Endocrinol. Invest. 2000, 23: 84–89.

    Article  CAS  PubMed  Google Scholar 

  42. Hochberg Z., Hertz P., Colin V., Ish-Shalom S., Yeshurun D., Youdim M.B.H., Amit T. The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-1 (IGF-I), and IGF-1 receptors in obesity and anorexia nervosa. Metabolism 1992, 41: 106–112.

    Article  CAS  PubMed  Google Scholar 

  43. Robinson I.C.A.F. Hypothalamic targets for growth hormone secretagogues. Acta Paediatr. 1997, 423 (Suppl.): 88–91.

    Article  CAS  Google Scholar 

  44. Casanueva F.F., Micic D., Pombo M., Leal A., Bokser L., Zugaza J.L., Dieguez C. Role of the new growth hormone-releasing secretagogues in the diagnosis of some hypothalamopituitary pathologies. Metabolism 1996, 8 (Suppl. 1): 123–126.

    Article  Google Scholar 

  45. Swaab D.F. Prader-Willi syndrome and the hypothalamus. Acta Paediatr. 1997, 423 (Suppl.): 50–54.

    Article  CAS  Google Scholar 

  46. Loche S., Balzano S., Bozzola M., Moretta A., Pintus S., Faedda A., Muntoni A., Carta D., Pintor C. Secretion of growth hormone releasing hormone in obese children. J. Endocrinol. Invest. 1992, 15: 453–457.

    Article  CAS  PubMed  Google Scholar 

  47. Procopio M., Ghigo E., Maccario M., Boffano G.M., Oleandri S.E., Arvat E., Bellone J., Mucci M., Boghen M.F., Camanni F. Effects of arginine, repeated growth hormone (GH)-releasing hormone (GHRH) administration and fasting on the acute GH response to GHRH in obesity. Proceedings International Congress on Growth Hormone and Somatomedins during Lifespan, Milan, Italy, 1992. J. Endocrinol. Invest. 1992, 15 (Suppl. 4): 47 (Abstract).

    Google Scholar 

  48. Low L.C.K., Wang C., Cheung P.T., Ho P., Lam K.S.L., Young R.T.T., Yeung C.Y., Ling N. Long-term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency. J. Clin. Endocrinol. Metab. 1988, 66: 611–617.

    Article  CAS  PubMed  Google Scholar 

  49. Goth M.I., Lyons C.E., Canny B.J., Thorner M.O. Pituitary adenylate cyclase activating polypeptide growth hormone(GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 1992, 130: 939–944.

    CAS  PubMed  Google Scholar 

  50. Mericq V., Cassorla F., Garcia H., Avila A., Bowers C.I., Merriam G.R. Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children. J. Clin. Endocrinol. Metab. 1995, 80: 1681–1684.

    CAS  PubMed  Google Scholar 

  51. Clark R.G., Carlsson L.M.S., Trojnar J., Robinson I.C.A.F. The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anaesthetized rats. J. Neuroendocrinol. 1989, 1: 249–255.

    Article  CAS  PubMed  Google Scholar 

  52. Ritzen E.M., Lindgren A.C., Hagenas L., Marcus C., Muller J., Blichfeldt S. Growth hormone treatment of patients with Prader-Willi syndrome. J. Pediatr. Endocrinol. Metab. 1999, 12: 345–349.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Auxology, IRCCS S. Giuseppe Hospital, Istituto Auxologico Italiano Foundation, P.O. Box 1, 28921, Verbania Intra, Italy

    Graziano Grugni, G. Guzzaloni & F. Morabito

Authors
  1. Graziano Grugni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Guzzaloni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Morabito
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Graziano Grugni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grugni, G., Guzzaloni, G. & Morabito, F. Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome. J Endocrinol Invest 24, 340–348 (2001). https://doi.org/10.1007/BF03343871

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343871

Key-words

Search

Navigation